OptimizeRx Corp
Company Stats
- Market Cap
- $157.3M
- as of Sep 30, 2026
- Shares Outstanding
- 18.8M
- Free Float
- 67.2%
Income Statement
- Revenue
- $109.4M
- Operating Income
- $11.7M
- Net Income
- $5.1M
- EBITDA
- $11.8M
- Non-cash Impairment
- $368,000
- Revenue Growth, 3Y
- 20.6%
- FCF Margin, 3Y Avg
- 4.0%
- FCF Margin, Worst Year
- -10.2%
Cash Flow
- Free Cash Flow
- $18.7M
- FCF Yield
- 11.9%
- Owner FCF Yield
- 7.4%
Balance Sheet
- Cash & Equivalents
- $23.4M
Returns & Capital
- SBC, 3Y Avg
- $10.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $109.4M | $18.7M | 17.0% |
| FY2024 | $92.1M | $4.8M | 5.2% |
| FY2023 | $71.5M | -$7.3M | -10.2% |
| FY2022 | $62.5M | $10.6M | 16.9% |
| FY2021 | $61.3M | $625,717 | 1.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 11, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Aci Lifts 2026 Guidance as Software Demand Stays Positive
Stronger demand supports expansion as pricing diverges